Abstract
The benefit of postoperative adjuvant chemotherapy with oxaliplatin (OX) for elderly patients with colorectal cancer (CRC) remains controversial. In meta-analyses of previous clinical trials, the benefit of adding OX to fluoropyrimidine (Fp) was not observed in elderly patients aged over 70 years because they died due to causes other than CRC. However, these clinical trials did not include Japanese patients. The aim of this study was to confirm the benefit of adding OX to Fp in the adjuvant setting for Japanese elderly patients with CRC because Japan is one of the countries with the highest average life expectancy (84.3 years according to WHO data in 2019).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
